20 May DFU Market in Europe set to increase 14.3%
Delveinsight Report names Biotherapy Services as one of the innovators in market sector set to increase by 14.1% by 2030
Healthcare and market research consultant, Delveignsight, released an analysis of the global DFU (Diabetic Foot Ulcer) market, naming Biotherapy Services as one of the key players in innovation technologies for new treatments. The report looks at historical and forecasted epidemiology trends in the developed world comprising; USA, EU-5 (United Kingdom, Germany, France, Italy and Spain) and Japan. It looks at the current situation, cost and market potential, and identifies the new innovative potential treatments stating that:
‘The DFU Market is set to change due to a rising awareness of the disease and incremental healthcare spending across the world’.
The report defines that diabetic foot ulcers (DFU’s) are open sores or wounds in patients with type 1 and type 2 diabetes mellitus, typically occurring after 10 years (average) of having the disease. The sore is routinely located on the base of the foot and complications occur because of the neuropathic and vascular complications associated with diabetes, this impairs the healing of the wound. Foot ulcers are commonly a complication of poorly controlled diabetes and DFU’s may result in infection or other complications that can lead to hospitalisation developing into complex, chronic wounds which have a major impact on morbidity, mortality and the quality of the patient’s life. In most DFU patients, peripheral neuropathy and peripheral arterial disease (PAD), or in some cases both, play a central role and DFU’s are therefore classified as three types: Neuropathic, Ischemic, and Neuro-ischemic.
According to the American Podiatric Medical Association (APMA) diabetes is:
‘the leading cause of non-traumatic lower extremity amputations in the United States, approximately 14-24% of patients developing a foot ulcer will require amputation’.
The report analyses the clinical and global economic burden of the disease. In the UK, £1 in every £140 of NHS spend goes on care for the diabetic foot, there were around 7 million prevalent DFU cases in 2020
The analysis predicts an expected increase in the market size in these seven major markets with a CAGR of 17% overall (14.1% in the EU-5 countries). The current cost of healthcare services is a major driving factor for the development of new treatments, with spending escalating for the treatment of DFU’s and amputations. The report evidences that 75-85% of cases of lower limb amputation are preceded by foot ulcers.
The report considers the Pipeline of products in development and includes Biotherapy Services, RAPIDTM Biodynamic Haematogel, stating: ‘some companies have indulged themselves to initiate clinical trials that investigate new treatment option’.
Biotherapy Services Ltd (BTS) is a clinical stage pharmaceutical biotechnology company developing novel autologous therapies for complex and chronic wounds, it has been awarded the innovative medicine designation – the Innovation Passport – for RAPIDTM Biodynamic Haematogel in the treatment of chronic ulceration of the diabetic foot.
More information about RAPID
More information about BTS
Read the report